Skip to main content
Contact Us
Subscribe
E-Edition
80°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ocugen
< Previous
1
2
3
Next >
Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders
June 09, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Business Advisory Board
June 05, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Pricing of $16.5 Million Public Offering of Common Stock
May 24, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Proposed Public Offering of Common Stock
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at BIO International Convention 2023
May 23, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with First Quarter 2023 Financial Results
May 05, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Friday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2023 Financial Results
April 28, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces OCU410ST Receives Orphan Drug Designation for Treatment of ABCA4-Associated Retinopathies
April 27, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor Conference
April 26, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
April 20, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Preliminary Safety and Efficacy Results from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis
April 14, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Virtual Investor & Analyst Event on April 14, 2023
April 11, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Chief Scientific Officer to Present at 2023 World Vaccine Congress
March 31, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces FDA Approval for Enrollment of Pediatric Patients in Ongoing OCU400 Phase 1/2 Clinical Trial for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)
March 27, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. to Participate in Fireside Chat at 35th Annual Roth Conference
March 07, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Appoints Quan A. Vu to Chief Financial Officer & Chief Business Officer
March 06, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update with Fourth Quarter and Full Year 2022 Financial Results
February 28, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. Announces Submission of Investigational New Drug Application with U.S. FDA to Initiate a Phase 1 Clinical Trial Evaluating OCU200 for the Treatment of Diabetic Macular Edema
February 27, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at Retinal Vascular Disease Drug Development Summit
February 17, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, February 28 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2022 Financial Results
February 15, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Appoints Quan A. Vu as Chief Business Officer
February 01, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference
January 31, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met
January 09, 2023
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Phase 3 Confirmatory Clinical Trial Agreement for NeoCart®
December 16, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen, Inc. to Ring the Nasdaq Stock Market Closing Bell
December 13, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Announces Update on OCU400 Phase 1/2 Clinical Trial Targeting Retinitis Pigmentosa and Leber Congenital Amaurosis
December 07, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Present at 3rd Annual Dry AMD Therapeutics Summit
November 28, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen Provides Business Update & Third Quarter 2022 Financial Results
November 08, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host Conference Call on Tuesday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2022 Financial Results
October 27, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
Ocugen to Host R&D Day in New York City on Tuesday, November 1, 2022
October 19, 2022
From
Ocugen
Via
GlobeNewswire
Tickers
OCGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.